Weve all heard that stopping taking a GLP-1 medication for weight losssuch as semaglutide (marketed as Wegovy) and tirzepatide (sold as Zepbound)often leads to rapid weight gain, with people returning to baseline in as little as 18 months
According to the literature addressing clinical trials, GI AEs usually develop in 4070% of treated patients, although they have sometimes been reported in up to 85% [9,10,11,12,13,14,15,16,17]
At NJ Advanced Surgical Solutions, serving patients throughout New Jersey, we help individuals explore effective weight-loss options and make informed decisions about their health
May improve cardiovascular and metabolic health, lowering risks of diabetes and heart disease 4